On 2/7/25, Neurocrine Biosciences Inc (NASDAQ: NBIX) stock suffered a major decline of -18.5%, closing at $122.62. Moreover, exceptionally high trading volume at 597% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and has declined -20.0% during the last week.
Current PriceTarget Research Rating
Neurocrine Biosciences has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Neurocrine Biosciences has a neutral Appreciation Score of 58 and a slightly negative Power Rating of 32, and the Low Neutral Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment